Onconox Inc. Appoints Vimta Labs as CRO Partner to Conduct 13-Week Inhalation Toxicology Study for OCN001

Summary

Onconox Inc. has selected Vimta Labs Ltd as its contract research organization (CRO) to conduct a pivotal 13-week inhalation toxicology study for its lung-cancer therapeutic candidate OCN001. Vimta’s established capability in inhalation product analysis, GLP-certified facilities, and comprehensive preclinical service suite enables Onconox to advance the program toward IND submission with rigorous, regulatory-aligned safety data.

Onconox Inc., a biotechnology company dedicated to advancing a novel lung cancer therapeutic candidate, today announced the appointment of Vimta Labs Ltd as its contract research partner to run a key 13-week inhalation toxicology study for OCN001.

Vimta has been selected for this study on account of its demonstrated expertise in inhalation product analysis and preclinical toxicology services. The company’s offering highlights dedicated inhalation testing capabilities, including dosing, aerosol generation, and device-formulation interfacing in accordance with regulatory standards. vimta.com In addition, Vimta operates a comprehensive preclinical research facility that is OECD GLP-certified and offers a full spectrum of toxicology, DMPK, and bioanalysis services. vimta.com

The 13-week repeat-dose inhalation study represents a major element of Onconox’s IND-enabling program for OCN001. By partnering with Vimta, Onconox aims to generate high-quality safety data in the relevant inhalation route, thereby de-risking the transition to first-in-human studies in patients with lung cancer.

Dr Sitaram Velaga, CEO of Onconox Inc., commented:"Selecting Vimta to conduct this 13-week inhalation toxicology study marks a pivotal step in advancing OCN001 toward clinical evaluation. Their specialized capabilities in inhalation testing and GLP-compliant environment give us confidence in both the integrity of the data and the readiness of our program for regulatory submission."

The collaboration with Vimta enables Onconox to consolidate formulation, device compatibility and inhaled-route toxicology under one integrated development plan. This supports the company’s capital-efficient strategy and focused approach to bringing OCN001 into the clinic in lung cancer.

Further updates on study initiation, timelines and development progress will be provided as Onconox delivers on its IND-enabling roadmap.